Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasoneindacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM) IRIDIUM trial investigators; Kerstjens, Huib A

Indacaterol provided clinically significant bronchodilation and improvements in dyspnoea and health status in Asian COPD patients.

No abstract

No abstract

Single dose indacaterol provided sustained 24-h bronchodilation with a faster onset of action than salmeterol and a good overall safety and tolerability profile in Japanese patients with asthma. These results are consistent with data from Caucasian populations.